Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease

Alzheimer’s disease is a neurological disorder that results in cognitive and behavioral impairment. Conventional treatment strategies, such as acetylcholinesterase inhibitor drugs, often fail due to their poor solubility, lower bioavailability, and ineffective ability to cross the blood–brain barrier. Nanotechnological treatment methods, which involve the design, characterization, production, and application of nanoscale drug delivery systems, have been employed to optimize therapeutics. These nanotechnologies include polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, microemulsion, nanoemulsion, and liquid crystals. Each of these are promising tools for the delivery of therapeutic devices to the brain via various routes of administration, particularly the intranasal route. The objective of this study is to present a systematic review of nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease.

[1]  W. H. Toliver,et al.  Liquid Crystals , 1912, Nature.

[2]  M. Kirschner,et al.  A protein factor essential for microtubule assembly. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Kreuter.  Nanoparticles and nanocapsules--new dosage forms in the nanometer size range. , 1978, Pharmaceutica acta Helvetiae.

[4]  F. Szoka,et al.  Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[5]  F. Szoka,et al.  Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. , 1979, Biochimica et biophysica acta.

[6]  L. Iversen,et al.  Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer type , 1980, Neuroscience Letters.

[7]  H. Henke,et al.  Cholinergic enzymes in neocortex, hippocampus and basal forebrain of non-neurological and senile dementia of alzheimer-type patients , 1983, Brain Research.

[8]  C. Mueller-Goymann,et al.  Interaction of lidocaine and lidocaine-HCl with the liquid crystal structure of topical preparations , 1986 .

[9]  R. Lévy,et al.  Computed Tomography in the Elderly , 1986, British Journal of Psychiatry.

[10]  J V Haxby,et al.  Rate of ventricular enlargement in dementia of the Alzheimer type correlates with rate of neuropsychological deterioration , 1987, Neurology.

[11]  H. Junginger,et al.  Characterization of liposomes. The influence of extrusion of multilamellar vesicles through polycarbonate membranes on particle size, particle size distribution and number of bilayers , 1987 .

[12]  M. Aprahamian,et al.  Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine , 1987, Biology of the cell.

[13]  W. Jagust,et al.  The diagnosis of dementia with single photon emission computed tomography. , 1987, Archives of neurology.

[14]  L. Thal,et al.  The Safety and Lack of Efficacy of Vinpocetine in Alzheimer's Disease , 1989, Journal of the American Geriatrics Society.

[15]  Martin Brandl,et al.  Liposome Preparation by a New High Pressure Homogenizer Gaulin Micron Lab 40 , 1990 .

[16]  G. Cevc,et al.  Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. , 1992, Biochimica et biophysica acta.

[17]  P. Watkins,et al.  Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. , 1994, JAMA.

[18]  K. Fleming,et al.  Dementia: diagnosis and evaluation. , 1995, Mayo Clinic proceedings.

[19]  P. Mcgeer,et al.  The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases , 1995, Brain Research Reviews.

[20]  Arto Mannermaa,et al.  A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein ε4 allele , 1995, Neuroscience Letters.

[21]  H. Soininen,et al.  A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele. , 1995, Neuroscience letters.

[22]  J. Kreuter,et al.  Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles) , 1995, Brain Research.

[23]  R. Koeppe,et al.  A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  G. Smistad,et al.  Bioadhesion of hydrated chitosans: An in vitro and in vivo study , 1996 .

[25]  M. Alonso,et al.  Novel hydrophilic chitosan‐polyethylene oxide nanoparticles as protein carriers , 1997 .

[26]  S. Hofmann,et al.  A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. , 1997, Neuropsychobiology.

[27]  L. Illum,et al.  Chitosan and its use as a pharmaceutical excipient. , 1998, Pharmaceutical research.

[28]  D. Hadler,et al.  Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. , 1998, Journal of neural transmission. Supplementum.

[29]  L. Nielsen,et al.  Bioadhesive drug delivery systems: I. Characterisation of mucoadhesive properties of systems based on glyceryl mono-oleate and glyceryl monolinoleate , 1998 .

[30]  R. Müller,et al.  Spray-drying of solid lipid nanoparticles (SLN TM). , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[31]  D. A. Kharkevich,et al.  Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. , 1998, Journal of microencapsulation.

[32]  J. D. Robertson,et al.  Copper, iron and zinc in Alzheimer's disease senile plaques , 1998, Journal of the Neurological Sciences.

[33]  Mandip Singh,et al.  Lipophilic drug derivatives in liposomes , 1998 .

[34]  D. Lasič.  Novel applications of liposomes. , 1998, Trends in biotechnology.

[35]  U. Kompella,et al.  Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? , 1998, Journal of drug targeting.

[36]  Yoshiaki,et al.  Preparation of poly(DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. , 1999, International journal of pharmaceutics.

[37]  Calum J. Drummond,et al.  Surfactant self-assembly objects as novel drug delivery vehicles , 1999 .

[38]  M. Johnstone,et al.  A central role for astrocytes in the inflammatory response to β-amyloid; chemokines, cytokines and reactive oxygen species are produced , 1999, Journal of Neuroimmunology.

[39]  C. Masters,et al.  Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. , 1999, The Journal of biological chemistry.

[40]  C. Nastruzzi,et al.  Preparation of liposomes by reverse-phase evaporation using alternative organic solvents. , 1999, Journal of microencapsulation.

[41]  D. Butterfield,et al.  Amyloid beta-peptide-associated free radical oxidative stress, neurotoxicity, and Alzheimer's disease. , 1999, Methods in enzymology.

[42]  C. Masters,et al.  Aqueous Dissolution of Alzheimer’s Disease Aβ Amyloid Deposits by Biometal Depletion* , 1999, The Journal of Biological Chemistry.

[43]  B. Winblad,et al.  The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease , 1999, International journal of geriatric psychiatry.

[44]  R. Bartus,et al.  Cholinergic markers in Alzheimer disease. , 1999, JAMA.

[45]  A. P. Vargas,et al.  Demência por neurossífilis: evolução clínica e neuropsicológica de um paciente , 2000 .

[46]  J. Kasbohm,et al.  Crystallographic investigation of cetylpalmitate solid lipid nanoparticles. , 2000, International journal of pharmaceutics.

[47]  B. Godin,et al.  Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[48]  L. Illum.  Transport of drugs from the nasal cavity to the central nervous system. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[49]  F. J. Carod-Artal,et al.  [Dementia caused by neurosyphilis: clinical and neuropsychological follow-up of a patient]. , 2000, Arquivos de neuro-psiquiatria.

[50]  R. Killiany,et al.  Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease , 2000, Annals of neurology.

[51]  K. Mäder,et al.  Solid lipid nanoparticles: production, characterization and applications. , 2001, Advanced drug delivery reviews.

[52]  O. Katare,et al.  Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. , 2001, International journal of pharmaceutics.

[53]  M. Brandl,et al.  Filter extrusion of liposomes using different devices: comparison of liposome size, encapsulation efficiency, and process characteristics. , 2001, International journal of pharmaceutics.

[54]  G. Ponchel,et al.  Combined hydroxypropyl-beta-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. , 2001, International journal of pharmaceutics.

[55]  B. Miller,et al.  CME Practice parameter : Diagnosis of dementia ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[56]  C. Masters,et al.  Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice , 2001, Neuron.

[57]  M. Beal,et al.  Metal Chelator Decreases Alzheimer β-Amyloid Plaques , 2001, Neuron.

[58]  R. Mrak,et al.  Interleukin-1, neuroinflammation, and Alzheimer’s disease , 2001, Neurobiology of Aging.

[59]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[60]  L. Lue,et al.  Microglial chemotaxis, activation, and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer's disease , 2001, Neurochemistry International.

[61]  R. Barnadas-Rodríguez,et al.  Factors involved in the production of liposomes with a high-pressure homogenizer. , 2001, International journal of pharmaceutics.

[62]  D M Chilukuri,et al.  Cubic phase gels as drug delivery systems. , 2001, Advanced drug delivery reviews.

[63]  Jeffrey L. Cummings,et al.  Practice parameter: Diagnosis of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[64]  R. Prost,et al.  Pictorial review of glutamate excitotoxicity: fundamental concepts for neuroimaging. , 2001, AJNR. American journal of neuroradiology.

[65]  D. Butterfield,et al.  Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death , 2002, Neurobiology of Aging.

[66]  Elias Fattal,et al.  Nanocapsule technology: a review. , 2002, Critical reviews in therapeutic drug carrier systems.

[67]  B. Lebowitz,et al.  Provisional diagnostic criteria for depression of Alzheimer disease. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[68]  M. Albert,et al.  MRI measures of entorhinal cortex vs hippocampus in preclinical AD , 2002, Neurology.

[69]  P. Spicer,et al.  Dry Powder Precursors of Cubic Liquid Crystalline Nanoparticles (cubosomes) , 2002 .

[70]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[71]  Xun Sun,et al.  Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[72]  J. Birks,et al.  Ginkgo biloba for cognitive impairment and dementia. , 2007, The Cochrane database of systematic reviews.

[73]  R. Müller,et al.  Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. , 2002, Advanced drug delivery reviews.

[74]  G. Small,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors , 2002, Clinical pharmacokinetics.

[75]  M. Trotta,et al.  Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. , 2003, International journal of pharmaceutics.

[76]  P. Whitehouse,et al.  Vinpocetine for cognitive impairment and dementia. , 2003, The Cochrane database of systematic reviews.

[77]  Gorka Orive,et al.  Drug delivery in biotechnology: present and future. , 2003, Current opinion in biotechnology.

[78]  T. Harkany,et al.  Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting beta-amyloid in Alzheimer's disease. , 2003, Neuroscience letters.

[79]  M N Rossor,et al.  The prevalence and causes of dementia in people under the age of 65 years , 2003, Journal of neurology, neurosurgery, and psychiatry.

[80]  T. Harkany,et al.  Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting β-amyloid in Alzheimer's disease , 2003, Neuroscience Letters.

[81]  Changsheng Xie,et al.  Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. , 2004, Biomaterials.

[82]  A. Vila,et al.  Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[83]  Kenjiro Ono,et al.  Curcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro , 2004, Journal of neuroscience research.

[84]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[85]  D. Aggarwal,et al.  Vesicular systems in ocular drug delivery: an overview. , 2004, International journal of pharmaceutics.

[86]  J. Kreuter,et al.  Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles , 1999, Pharmaceutical Research.

[87]  R. Veerhuis,et al.  How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes , 2004, Aging cell.

[88]  Geoffrey Lee.  Surfactants and Polymers in Drug Delivery , 2004 .

[89]  M. Mattson.  Pathways towards and away from Alzheimer's disease , 2004, Nature.

[90]  O. Forlenza,et al.  Platelet phospholipase A2 activity in Alzheimer’s disease and mild cognitive impairment , 2004, Journal of Neural Transmission.

[91]  P. I. Costa,et al.  Improvement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomes. , 2005, International journal of pharmaceutics.

[92]  Gary M Pollack,et al.  Nasal drug administration: potential for targeted central nervous system delivery. , 2005, Journal of pharmaceutical sciences.

[93]  E. Allémann,et al.  Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[94]  R. Levy,et al.  Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer's disease , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[95]  H. Arias,et al.  The role of inflammation in Alzheimer's disease. , 2005, The international journal of biochemistry & cell biology.

[96]  Fusheng Yang,et al.  Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo* , 2005, Journal of Biological Chemistry.

[97]  Rubiana M Mainardes,et al.  PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. , 2005, International journal of pharmaceutics.

[98]  R. C. Evangelista,et al.  Praziquantel-loaded PLGA nanoparticles: preparation and characterization , 2005, Journal of microencapsulation.

[99]  J. Sotolongo,et al.  Preparation of plasmid DNA-containing liposomes using a high-pressure homogenization--extrusion technique. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[100]  J. Smart.  The basics and underlying mechanisms of mucoadhesion. , 2005, Advanced drug delivery reviews.

[101]  W. Lu,et al.  Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier. , 2005, International journal of pharmaceutics.

[102]  S. Lipton.  The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. , 2005, Current Alzheimer research.

[103]  Rakesh K. Sharma,et al.  Pharmacoscintigraphic evaluation of polysorbate80-coated chitosan nanoparticles for brain targeting , 2005 .

[104]  F. Simons,et al.  Hydroxyzine- and Cetirizine-Loaded Liposomes: Effect of Duration of Thin Film Hydration, Freeze-Thawing, and Changing Buffer pH on Encapsulation and Stability , 2005, Drug development and industrial pharmacy.

[105]  J. Molinuevo,et al.  Memantine: Targeting glutamate excitotoxicity in Alzheimer's disease and other dementias , 2005, American journal of Alzheimer's disease and other dementias.

[106]  Wei Lu,et al.  Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. , 2006, Biomaterials.

[107]  C. Drummond,et al.  Ordered 2-D and 3-D nanostructured amphiphile self-assembly materials stable in excess solvent. , 2006, Physical chemistry chemical physics : PCCP.

[108]  S. Naik,et al.  Evaluation of antioxidant activity of Ginkgo biloba phytosomes in rat brain , 2006, Phytotherapy research : PTR.

[109]  Xinguo Jiang,et al.  Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. , 2006, International journal of pharmaceutics.

[110]  Maria Palmira Daflon Gremião,et al.  Liposomes and micro/nanoparticles as colloidal carriers for nasal drug delivery. , 2006, Current drug delivery.

[111]  Connie B. Chang,et al.  Nanoemulsions: formation, structure, and physical properties , 2006 .

[112]  A. Periclou,et al.  Pharmacokinetic study of memantine in healthy and renally impaired subjects , 2006, Clinical pharmacology and therapeutics.

[113]  S. Parveen,et al.  Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. , 2006, Clinical pharmacokinetics.

[114]  M. Chorilli,et al.  Study of liposomes stability containing soy phosphatidyleholine and hydrogenated soy phosphatydylcholine adding or not cholesterol by turbidity method , 2007 .

[115]  R. Glockshuber,et al.  Amyloid-beta aggregation. , 2007, Neuro-degenerative diseases.

[116]  K. Jain,et al.  Nanobiotechnology-Based Drug Delivery to the Central Nervous System , 2007, Neurodegenerative Diseases.

[117]  J. Cummings,et al.  Positron emission tomography metabolic correlates of apathy in Alzheimer disease. , 2007, Archives of neurology.

[118]  S. Guterres,et al.  Polymeric Nanoparticles, Nanospheres and Nanocapsules, for Cutaneous Applications , 2007, Drug target insights.

[119]  Guy C. Brown,et al.  Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria , 2003, Molecular Neurobiology.

[120]  J. Craig,et al.  Phase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation. , 2007, International journal of pharmaceutics.

[121]  S. Stegemann,et al.  When poor solubility becomes an issue: from early stage to proof of concept. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[122]  Bruce L. Miller,et al.  Appendix B: Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the quality standards subcommittee of the American academy neurology , 2007 .

[123]  Martin Malmsten,et al.  Phase Transformations in Self‐Assembly Systems for Drug Delivery Applications , 2007 .

[124]  J. Trojanowski,et al.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.

[125]  Yamsani Madhusudan Rao,et al.  Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics. , 2007, International journal of pharmaceutics.

[126]  Chris G. Parsons,et al.  Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse , 2007, Neuropharmacology.

[127]  Ji Guo,et al.  Nanofabricated particles for engineered drug therapies: a preliminary biodistribution study of PRINT nanoparticles. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[128]  Nick C Fox,et al.  Amyloid, hypometabolism, and cognition in Alzheimer disease , 2007, Neurology.

[129]  P. Raina,et al.  Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline , 2008, Annals of Internal Medicine.

[130]  J. Bara,et al.  Liquid crystalline functional assemblies and their supramolecular structures , 2008 .

[131]  J. Grimley Evans,et al.  Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. , 2008, The Cochrane database of systematic reviews.

[132]  David S. Jones,et al.  Precursor system of liquid crystalline phase containing propolis microparticles for the treatment of periodontal disease: development and characterization. , 2008, Drug development and industrial pharmacy.

[133]  M. Samanta,et al.  Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[134]  R. Hashizume,et al.  Intranasal Delivery—A New Therapeutic Approach for Brain Tumors , 2008 .

[135]  J. Drewe,et al.  Pharmacokinetics and metabolism of idebenone in healthy male subjects , 2009, European Journal of Clinical Pharmacology.

[136]  C. Parsons,et al.  Pharmacodynamics of Memantine: An Update , 2008, Current neuropharmacology.

[137]  A. Misra,et al.  Intranasal Mucoadhesive Microemulsion of Tacrine to Improve Brain Targeting , 2008, Alzheimer disease and associated disorders.

[138]  G. Bartzokis,et al.  Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria. , 2008, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[139]  V. Cardile,et al.  Improved adhesion to mucosal cells of water-soluble chitosan tetraalkylammonium salts. , 2008, International journal of pharmaceutics.

[140]  Amir Nazem,et al.  Nanotechnology solutions for Alzheimer's disease: advances in research tools, diagnostic methods and therapeutic agents. , 2008, Journal of Alzheimer's disease : JAD.

[141]  N. Udupa,et al.  A study of rivastigmine liposomes for delivery into the brain through intranasal route , 2008, Acta pharmaceutica.

[142]  M. Samanta,et al.  Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease , 2008, Brain Research.

[143]  M. Barbi,et al.  LC Evaluation of In Vitro Release of AZT from Microemulsions , 2009 .

[144]  H. Kavirajan.  Memantine: a comprehensive review of safety and efficacy. , 2009, Expert opinion on drug safety.

[145]  D. Begley,et al.  Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[146]  E. Souto,et al.  Improving oral absorption of Salmon calcitonin by trimyristin lipid nanoparticles. , 2009, Journal of biomedical nanotechnology.

[147]  E. Barbu,et al.  The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier. , 2009, Expert opinion on drug delivery.

[148]  Amber L. Doiron,et al.  Controlled Release and Nanotechnology , 2009 .

[149]  F. Ahmad,et al.  CNS drug delivery systems: novel approaches. , 2009, Recent patents on drug delivery & formulation.

[150]  J Driver,et al.  Modulation of fusiform cortex activity by cholinesterase inhibition predicts effects on subsequent memory. , 2009, Brain : a journal of neurology.

[151]  Lisbeth Illum,et al.  Nanoparticles for direct nose-to-brain delivery of drugs. , 2009, International journal of pharmaceutics.

[152]  Hong-Zhuan Chen,et al.  Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: an updated meta-analysis , 2009, Journal of Neural Transmission.

[153]  G. Giammona,et al.  Ferulic Acid-Loaded Lipid Nanostructures as Drug Delivery Systems for Alzheimers Disease: Preparation, Characterization and Cytotoxicity Studies , 2009 .

[154]  M. Gremião,et al.  Development and validation of HPLC method for analysis of dexamethasone acetate in microemulsions , 2009 .

[155]  J. Pardeike,et al.  Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. , 2009, International journal of pharmaceutics.

[156]  Otto Glatter,et al.  Characterization and potential applications of nanostructured aqueous dispersions. , 2009, Advances in colloid and interface science.

[157]  Jagdish Singh,et al.  Various Pharmaceutical Disperse Systems , 2010 .

[158]  S. de Santi,et al.  Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. , 2010, Journal of Alzheimer's disease : JAD.

[159]  T. Aminabhavi,et al.  Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease. , 2010, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[160]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[161]  Javed Ali,et al.  Strategy for effective brain drug delivery. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[162]  W. Scheper,et al.  Nanoparticles against Alzheimer's disease: PEG-PACA nanoparticles are able to link the aβ-peptide and influence its aggregation kinetic. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[163]  M. Barbi,et al.  Surfactant systems for nasal zidovudine delivery: structural, rheological and mucoadhesive properties , 2010, The Journal of pharmacy and pharmacology.

[164]  V. Kadam,et al.  Brain Drug Delivery System: An Overview , 2010 .

[165]  M. Barbi,et al.  Development and in vitro evaluation of surfactant systems for controlled release of zidovudine. , 2010, Journal of pharmaceutical sciences.

[166]  J. Simon,et al.  Resveratrol lowers beta-amyloid accumulation and deposition in vivo by controlling AMPK signaling , 2010, Alzheimer's & Dementia.

[167]  W. Scheper,et al.  New method based on capillary electrophoresis with laser-induced fluorescence detection (CE-LIF) to monitor interaction between nanoparticles and the amyloid-β peptide. , 2010, Analytical chemistry.

[168]  Sandip S Chavhan,et al.  Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[169]  R. D. de Freitas,et al.  Antioxidant idebenone-loaded nanoparticles based on chitosan and N-carboxymethylchitosan. , 2010, Nanomedicine : nanotechnology, biology, and medicine.

[170]  Z. Zuo,et al.  Intranasal Delivery—Modification of Drug Metabolism and Brain Disposition , 2010, Pharmaceutical Research.

[171]  Xiaoning Zhang,et al.  Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. , 2010, International journal of pharmaceutics.

[172]  S. Yılmaz,et al.  Investigation of liposome formulation effects on rivastigmine transport through human colonic adenocarcinoma cell line (CACO-2). , 2010, Die Pharmazie.

[173]  S. Lipton,et al.  Memantine Preferentially Blocks Extrasynaptic over Synaptic NMDA Receptor Currents in Hippocampal Autapses , 2010, The Journal of Neuroscience.

[174]  G. Giammona,et al.  Brain-targeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution. , 2010, Nanomedicine.

[175]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[176]  M. Gremião,et al.  Mucoadhesive drug delivery systems , 2010 .

[177]  George Alexeeff,et al.  Nanotechnology and nanomaterials: toxicology, risk assessment, and regulations. , 2010, Journal of nanoscience and nanotechnology.

[178]  M. Khan,et al.  Non-destructive methods of characterization of risperidone solid lipid nanoparticles. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[179]  I. Grundke‐Iqbal,et al.  Targeting Tau Protein in Alzheimer’s Disease , 2010, Drugs & aging.

[180]  D. Paolino,et al.  Supramolecular devices to improve the treatment of brain diseases. , 2011, Drug discovery today.

[181]  Amandeep Singh,et al.  Nanotechnology Based Targeted Drug Delivery: Current Status and Future Prospects for Drug Development , 2011 .

[182]  J. Sousa,et al.  The size of solid lipid nanoparticles: an interpretation from experimental design. , 2011, Colloids and surfaces. B, Biointerfaces.

[183]  J. Estelrich,et al.  Magnetoliposomes prepared by reverse-phase followed by sequential extrusion: characterization and possibilities in the treatment of inflammation. , 2011, International journal of pharmaceutics.

[184]  A. Pohlmann,et al.  Incorporation of resveratrol into lipid-core nanocapsules improves its cerebral bioavailability and reduces the Aβ-induced toxicity , 2011, Alzheimer's & Dementia.

[185]  R. Tan,et al.  Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. , 2011, Colloids and surfaces. B, Biointerfaces.

[186]  Xiaohui Hu,et al.  Coenzyme Q10 nanoparticles prepared by a supercritical fluid-based method , 2011 .

[187]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[188]  Rahamatullah Shaikh,et al.  Mucoadhesive drug delivery systems , 2011, Journal of pharmacy & bioallied sciences.

[189]  Susan E. Hahn,et al.  Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors: Erratum , 2011, Genetics in Medicine.

[190]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[191]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[192]  M. Gremião,et al.  Thermal characterization of solid lipid nanoparticles containing praziquantel , 2012, Journal of Thermal Analysis and Calorimetry.

[193]  Tyler E. Benedum,et al.  Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent. , 2011, Seminars in nuclear medicine.

[194]  Richard Mayeux,et al.  Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors , 2011, Genetics in Medicine.

[195]  Patrick Couvreur,et al.  Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[196]  B. Winslow,et al.  Treatment of Alzheimer disease. , 2011, American family physician.

[197]  J. Huwyler,et al.  Drug transport to brain with targeted liposomes , 2011, NeuroRX.

[198]  Zheng Zachory Wei,et al.  Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer's disease. , 2011, Current Alzheimer research.

[199]  G. Léger,et al.  Pharmacological Treatment of Alzheimer Disease , 2011, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[200]  M. Gremião,et al.  Loading of praziquantel in the crystal lattice of solid lipid nanoparticles , 2012, Journal of Thermal Analysis and Calorimetry.

[201]  Mingshi Yang,et al.  Novel mucus-penetrating liposomes as a potential oral drug delivery system: preparation, in vitro characterization, and enhanced cellular uptake , 2011, International journal of nanomedicine.

[202]  Wenzhong Zhou,et al.  Preparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: influences of fatty acids. , 2011, Colloids and surfaces. B, Biointerfaces.

[203]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[204]  M. Gobbi,et al.  Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide. , 2011, Biomaterials.

[205]  C. Sharma,et al.  Enhanced delivery of lopinavir to the CNS using Compritol-based solid lipid nanoparticles. , 2011, Therapeutic delivery.

[206]  S. Yılmaz,et al.  New perspective for the treatment of Alzheimer diseases: Liposomal rivastigmine formulations , 2011, Drug development and industrial pharmacy.

[207]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[208]  R. Narang,et al.  Sci Pharm www.scipharm.at Research article Open Access Amoxicillin Loaded Chitosan–Alginate Polyelectrolyte Complex Nanoparticles as , 2022 .

[209]  Nick C Fox,et al.  The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease , 2011 .

[210]  Y. Kuo,et al.  Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. , 2011, Biomaterials.

[211]  Kakkar Vandita,et al.  Enhanced apoptotic effect of curcumin loaded solid lipid nanoparticles. , 2012, Molecular pharmaceutics.

[212]  T. Wyss-Coray,et al.  Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. , 2012, Cold Spring Harbor perspectives in medicine.

[213]  C. Spuch,et al.  Advances in the treatment of neurodegenerative disorders employing nanoparticles. , 2012, Recent patents on drug delivery & formulation.

[214]  M. Nireekshan Kumar,et al.  Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[215]  D. Cui,et al.  Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles , 2012, International journal of nanomedicine.

[216]  M. Khan,et al.  Predicting hydrophilic drug encapsulation inside unilamellar liposomes. , 2012, International journal of pharmaceutics.

[217]  U. Krishnan,et al.  Liposomal delivery of a beta sheet blocker peptide for the treatment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[218]  Svetlana Gelperina,et al.  Transport of drugs across the blood-brain barrier by nanoparticles. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[219]  R. Tan,et al.  Solid lipid nanoparticles: continuous and potential large-scale nanoprecipitation production in static mixers. , 2012, Colloids and surfaces. B, Biointerfaces.

[220]  S. Baboota,et al.  Nanostructure-based drug delivery systems for brain targeting , 2012, Drug development and industrial pharmacy.

[221]  G. Salzano,et al.  Nanotechnologies: a strategy to overcome blood-brain barrier. , 2012, Current drug metabolism.

[222]  P. Gaillard,et al.  Targeted blood-to-brain drug delivery --10 key development criteria. , 2012, Current pharmaceutical biotechnology.

[223]  L. Soares,et al.  Agitation during lipoplex formation harmonizes the interaction of siRNA to cationic liposomes. , 2012, International journal of pharmaceutics.

[224]  N. Garti,et al.  Lipid polymorphism in lyotropic liquid crystals for triggered release of bioactives. , 2012, Food & function.

[225]  M. Gremião,et al.  Nanoencapsulation and characterization of zidovudine on poly(L-lactide) and poly(L-lactide)-poly(ethylene glycol)-blend nanoparticles. , 2012, Journal of nanoscience and nanotechnology.

[226]  Xueling Dai,et al.  Protective Effects of Curcumin on Amyloid-β-Induced Neuronal Oxidative Damage , 2012, Neurochemical Research.

[227]  Patrícia Severino,et al.  Preparação de nanopartículas poliméricas a partir da polimerização de monômeros - Parte I , 2012 .

[228]  M. Brandl,et al.  Brain delivery of camptothecin by means of solid lipid nanoparticles: formulation design, in vitro and in vivo studies. , 2012, International journal of pharmaceutics.

[229]  Sandip S. Chavan,et al.  Preparation and characterization of solid lipid nanoparticle-based nasal spray of budesonide , 2013, Drug Delivery and Translational Research.

[230]  D. Svirskis,et al.  In-situ phase transition from microemulsion to liquid crystal with the potential of prolonged parenteral drug delivery. , 2012, International journal of pharmaceutics.

[231]  Jijin Gu,et al.  The brain targeting mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles. , 2012, Biomaterials.

[232]  H. Fessi,et al.  Redispersible lipid nanoparticles of Spironolactone obtained by three drying methods , 2012 .

[233]  David A Bennett,et al.  Correlation of Amyloid PET Ligand Florbetapir F 18 Binding With A&bgr; Aggregation and Neuritic Plaque Deposition in Postmortem Brain Tissue , 2012, Alzheimer disease and associated disorders.

[234]  Karsten Mäder,et al.  Solid lipid nanoparticles , 2012 .

[235]  M. Sabitha,et al.  CURRENT TRENDS IN LIPID BASED DELIVERY SYSTEMS AND ITS APPLICATIONS IN DRUG DELIVERY , 2012 .

[236]  Saahil Arora,et al.  Dermal delivery of drugs using different vesicular carriers: A comparative review , 2012 .

[237]  G. Luo,et al.  Microemulsion-based patch for transdermal delivery of huperzine A and ligustrazine phosphate in treatment of Alzheimer’s disease , 2012, Drug development and industrial pharmacy.

[238]  J. Morillas-Ruiz,et al.  A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines , 2012, TheScientificWorldJournal.

[239]  S. Saraf,et al.  SLN approach for nose-to-brain delivery of alprazolam , 2012, Drug Delivery and Translational Research.

[240]  M. Sabbagh,et al.  New Acetylcholinesterase Inhibitors for Alzheimer's Disease , 2011, International journal of Alzheimer's disease.

[241]  D. Mcclements.  Nanoemulsions versus microemulsions: terminology, differences, and similarities , 2012 .

[242]  L. Chew,et al.  The effect of curcumin on the stability of Aβ dimers. , 2012, The journal of physical chemistry. B.

[243]  R. Reul,et al.  Formulation optimization of itraconazole loaded PEGylated liposomes for parenteral administration by using design of experiments. , 2013, International journal of pharmaceutics.

[244]  S. Ghanbarzadeh,et al.  Application of response surface methodology in development of sirolimus liposomes prepared by thin film hydration technique. , 2013, BioImpacts : BI.

[245]  B. Nordestgaard,et al.  Apolipoprotein E plasma level and genotype —/INS; Risk of dementia in 76,000 individuals from the general population , 2013, Journal of the Neurological Sciences.

[246]  R. Tan,et al.  Scalable ionic gelation synthesis of chitosan nanoparticles for drug delivery in static mixers. , 2013, Carbohydrate polymers.

[247]  Nanotechnology for CNS delivery of bio-therapeutic agents , 2013, Drug Delivery and Translational Research.

[248]  M. Masserini.  Nanoparticles for Brain Drug Delivery , 2013, ISRN biochemistry.

[249]  A. ElMeshad,et al.  Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer’s disease , 2013, International journal of nanomedicine.

[250]  S. Mangal,et al.  Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[251]  Qing-Wen Zhang,et al.  Curcumin-loaded solid lipid nanoparticles have prolonged in vitro antitumour activity, cellular uptake and improved in vivo bioavailability. , 2013, Colloids and surfaces. B, Biointerfaces.

[252]  V. Vasić,et al.  Send Orders of Reprints at Reprints@benthamscience.net Acetylcholinesterase Inhibitors: Pharmacology and Toxicology , 2022 .

[253]  A. Banerjee,et al.  Antioxidant role of amyloid β protein in cell-free and biological systems: implication for the pathogenesis of Alzheimer disease. , 2013, Free radical biology & medicine.

[254]  C. Iorio,et al.  Lipid nanoparticles production by supercritical fluid assisted emulsion–diffusion , 2013 .

[255]  Yeon-Ji Jo,et al.  Characterization of β-carotene nanoemulsions prepared by microfluidization technique , 2014, Food Science and Biotechnology.

[256]  M. Gremião,et al.  Nasal administration of liquid crystal precursor mucoadhesive vehicle as an alternative antiretroviral therapy. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[257]  W. Thies,et al.  2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.

[258]  B. Zhang,et al.  LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma. , 2013, Biomaterials.

[259]  X. Qi,et al.  Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. , 2013, International journal of pharmaceutics.

[260]  M. Masserini,et al.  Functionalization with TAT-peptide enhances blood-brain barrier crossing in vitro of nanoliposomes carrying a curcumin-derivative to bind amyloid-β peptide , 2013 .

[261]  J. DeSimone,et al.  Development of a nanoparticle-based influenza vaccine using the PRINT technology. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[262]  V. Pillay,et al.  Ligand-functionalized nanoliposomes for targeted delivery of galantamine. , 2013, International journal of pharmaceutics.

[263]  O. Forlenza,et al.  Low platelet iPLA2 activity predicts conversion from mild cognitive impairment to Alzheimer’s disease: a 4-year follow-up study , 2014, Journal of Neural Transmission.

[264]  Vikrant Saluja,et al.  Patents on brain permeable nanoparticles. , 2014, Recent patents on CNS drug discovery.

[265]  Hao Peng,et al.  The formulation and delivery of curcumin with solid lipid nanoparticles for the treatment of on non-small cell lung cancer both in vitro and in vivo. , 2013, Materials science & engineering. C, Materials for biological applications.

[266]  Sandra Rocha,et al.  Targeted drug delivery across the blood brain barrier in Alzheimer's disease. , 2013, Current pharmaceutical design.

[267]  J. Ramirez-Vick,et al.  Evaluation of the cytotoxic effect of camptothecin solid lipid nanoparticles on MCF7 cells , 2013, Drug delivery.

[268]  A. Fadda,et al.  Liposomes for brain delivery , 2013, Expert opinion on drug delivery.

[269]  A. Bush.  The metal theory of Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[270]  M. Yasir,et al.  Glyceryl monostearate based nanoparticles of mefenamic acid: Fabrication and in vitro characterization , 2013 .

[271]  K. Jain.  Applications of Biotechnology in Neurology , 2013, Humana Press.

[272]  Anilda Guri,et al.  Utilization of solid lipid nanoparticles for enhanced delivery of curcumin in cocultures of HT29-MTX and Caco-2 cells. , 2013, Food & function.

[273]  M. Masserini,et al.  Liposomes functionalized to overcome the blood–brain barrier and to target amyloid-β peptide: the chemical design affects the permeability across an in vitro model , 2013, International journal of nanomedicine.

[274]  Lirong Teng,et al.  Development of a novel niosomal system for oral delivery of Ginkgo biloba extract , 2013, International journal of nanomedicine.

[275]  Richard S. Frackowiak,et al.  Generative FDG-PET and MRI Model of Aging and Disease Progression in Alzheimer's Disease , 2013, PLoS Comput. Biol..

[276]  C. Duyckaerts,et al.  Curcumin-conjugated nanoliposomes with high affinity for Aβ deposits: possible applications to Alzheimer disease. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[277]  B. Sarmento,et al.  Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[278]  V. Patravale,et al.  Comparative in vitro and in vivo evaluation of lipid based nanocarriers of Huperzine A. , 2013, International journal of pharmaceutics.

[279]  M. Yasir,et al.  Preparation and optimization of haloperidol loaded solid lipid nanoparticles by Box–Behnken design , 2013 .

[280]  B. Ahmed,et al.  Preparation, characterization, in vivo and biochemical evaluation of brain targeted Piperine solid lipid nanoparticles in an experimentally induced Alzheimer’s disease model , 2013, Journal of drug targeting.

[281]  K. Gowthamarajan,et al.  Delivery of neuroprotective polyphenol to the brain via an intranasal route for management of Alzheimer's disease , 2013, Alzheimer's & Dementia.

[282]  M. Chorilli,et al.  Caffeine Encapsulated in Small Unilamellar Liposomes: Characerization and In Vitro Release Profile , 2013 .

[283]  S. Tayebati,et al.  Intranasal drug delivery to the central nervous system: present status and future outlook. , 2012, Current pharmaceutical design.

[284]  T. Rades,et al.  Characterization and in vitro permeation study of microemulsions and liquid crystalline systems containing the anticholinesterase alkaloidal extract from Tabernaemontana divaricata. , 2013, International journal of pharmaceutics.

[285]  Keith A. Johnson,et al.  Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging , 2013, Alzheimer's & Dementia.

[286]  N. Cho,et al.  Comparison of Extruded and Sonicated Vesicles for Planar Bilayer Self-Assembly , 2013, Materials.

[287]  B. Isailovic,et al.  Resveratrol loaded liposomes produced by different techniques , 2013 .

[288]  M. Walsh,et al.  Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[289]  M. Haritha,et al.  Formulation and evaluation of niosomal nasal drug delivery system of folic acid for brain targeting. , 2013, Current drug discovery technologies.

[290]  K. Chopra,et al.  Curcumin loaded solid lipid nanoparticles: an efficient formulation approach for cerebral ischemic reperfusion injury in rats. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[291]  M. Salmona,et al.  Mono and Dually Decorated Nanoliposomes for Brain Targeting, In Vitro and In Vivo Studies , 2013, Pharmaceutical Research.

[292]  K. Gowthamarajan,et al.  Curcumin-donepezil–loaded nanostructured lipid carriers for intranasal delivery in an Alzheimer's disease model , 2013, Alzheimer's & Dementia.

[293]  D. Stepensky,et al.  Quantitative analysis of the brain-targeted delivery of drugs and model compounds using nano-delivery systems. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[294]  A. Silva,et al.  Nanoemulsions for delivery of flavonoids: formulation and in vitro release of rutin as model drug , 2014, Pharmaceutical development and technology.

[295]  K. Gowthamarajan,et al.  Intranasal therapeutic strategies for management of Alzheimer’s disease , 2014, Journal of drug targeting.

[296]  Hyun Jin Park,et al.  Factors influencing the physicochemical characteristics of cationic polymer-coated liposomes prepared by high-pressure homogenization , 2014 .

[297]  郑俊海,et al.  科技期刊稿件处理的精细化管理——《International Journal of Nanomedicine〉〉投稿体会 , 2014 .

[298]  M. Coelho,et al.  Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies. , 2014, Nanomedicine.

[299]  Qizhi Zhang,et al.  Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice. , 2014, Biomaterials.

[300]  P. Labbé,et al.  On the mucoadhesive properties of chitosan-coated polycaprolactone nanoparticles loaded with curcumin using quartz crystal microbalance with dissipation monitoring. , 2014, Journal of biomedical nanotechnology.

[301]  M. E. Ali,et al.  Spray freeze drying for dry powder inhalation of nanoparticles. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[302]  K. Dawson,et al.  Designing the future of nanomedicine: current barriers to targeted brain therapeutics , 2014 .

[303]  Kazuaki Ninomiya,et al.  Ultrasound-mediated drug delivery using liposomes modified with a thermosensitive polymer. , 2014, Ultrasonics sonochemistry.

[304]  Xiang Ma,et al.  Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting , 2014, International journal of nanomedicine.

[305]  Y. Kuo,et al.  Delivering etoposide to the brain using catanionic solid lipid nanoparticles with surface 5-HT-moduline. , 2014, International journal of pharmaceutics.

[306]  Zhang Long-ka.  Evaluation of brain-targeting of β-asarone microemulsion by intranasal administration , 2014 .

[307]  Danhui Li,et al.  Deformable liposomes by reverse-phase evaporation method for an enhanced skin delivery of (+)-catechin , 2014, Drug development and industrial pharmacy.

[308]  Anton P. J. Middelberg,et al.  Towards designer nanoemulsions for precision delivery of therapeutics , 2014 .

[309]  Javed Ali,et al.  Insights into direct nose to brain delivery: current status and future perspective , 2014, Drug delivery.

[310]  R. Müller,et al.  Solid lipid nanoparticles (SLN) stabilized with polyhydroxy surfactants: Preparation, characterization and physical stability investigation , 2014 .

[311]  M. Gremião,et al.  In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment. , 2014, International journal of pharmaceutics.

[312]  D. Stepensky,et al.  Quantitative analysis of drug delivery to the brain via nasal route. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[313]  Xin-guo Jiang,et al.  Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease. , 2014, International journal of pharmaceutics.

[314]  Charles Duyckaerts,et al.  Multifunctional nanoliposomes with curcumin-lipid derivative and brain targeting functionality with potential applications for Alzheimer disease. , 2014, European journal of medicinal chemistry.

[315]  Flávia Chiva Carvalho,et al.  Plataformas bio(muco) adesivas poliméricas baseadas em nanotecnologia para liberação controlada de fármacos - propriedades, metodologias e aplicações , 2014 .

[316]  M. Colombo,et al.  Optimization of Copaiba oil-based nanoemulsions obtained by different preparation methods , 2014 .

[317]  I. Norton,et al.  Production of water-in-oil nanoemulsions using high pressure homogenisation: A study on droplet break-up , 2014 .

[318]  J. Safari,et al.  Advanced drug delivery systems: Nanotechnology of health design A review , 2014 .

[319]  A. Alshamsan.  Nanoprecipitation is more efficient than emulsion solvent evaporation method to encapsulate cucurbitacin I in PLGA nanoparticles. , 2014, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[320]  M. Kamal,et al.  Role of nanomedicines in delivery of anti-acetylcholinesterase compounds to the brain in Alzheimer's disease. , 2014, CNS & neurological disorders drug targets.

[321]  Renad Alyautdin,et al.  Nanoscale drug delivery systems and the blood–brain barrier , 2014, International journal of nanomedicine.

[322]  M. V. Scarpa,et al.  Development and characterization of biocompatible isotropic and anisotropic oil-in-water colloidal dispersions as a new delivery system for methyl dihydrojasmonate antitumor drug , 2014, International journal of nanomedicine.

[323]  H. Moghimi,et al.  Formulation, Characterization and Optimization of Liposomes Containing Eicosapentaenoic and Docosahexaenoic Acids; A Methodology Approach , 2014, Iranian journal of pharmaceutical research : IJPR.

[324]  J. Arias.  Key Aspects in Nanotechnology and Drug Delivery , 2014 .

[325]  M. Joshi,et al.  Nanocarrier-based approaches for treatment and detection of Alzheimer's disease. , 2014, Journal of nanoscience and nanotechnology.

[326]  R. Bălașa.  NANONEUROLOGY , 2015, Romanian Journal of Neurology.

[327]  M. Gremião,et al.  Nanostructured Lipid Carriers as a Strategy to Improve the In Vitro Schistosomiasis Activity of Praziquantel. , 2015, Journal of nanoscience and nanotechnology.

[328]  M. Srinivasan,et al.  Significance of NF-κB as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimer’s disease and multiple sclerosis , 2015, Expert opinion on therapeutic targets.

[329]  Yahya E Choonara,et al.  Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures , 2015, International journal of nanomedicine.

[330]  B. Bleier,et al.  The Blood-Brain Barrier and Nasal Drug Delivery to the Central Nervous System , 2015, American journal of rhinology & allergy.

[331]  E. Shusta,et al.  Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier. , 2015, Annual review of pharmacology and toxicology.

[332]  N. Saunders.  Faculty of 1000 evaluation for Getting into the brain: approaches to enhance brain drug delivery. , 2016 .

[333]  Nannan Zheng,et al.  Curcumin-loaded solid lipid nanoparticles with Brij78 and TPGS improved in vivo oral bioavailability and in situ intestinal absorption of curcumin , 2016, Drug delivery.